A
Adrian Heilbut
Researcher at Broad Institute
Publications - 14
Citations - 7391
Adrian Heilbut is an academic researcher from Broad Institute. The author has contributed to research in topics: Proteomics & Gene. The author has an hindex of 13, co-authored 14 publications receiving 7012 citations. Previous affiliations of Adrian Heilbut include Harvard University & Boston University.
Papers
More filters
Journal ArticleDOI
Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry
Yuen Ho,Albrecht Gruhler,Adrian Heilbut,Gary D. Bader,Gary D. Bader,Lynda Moore,Sally-Lin Adams,Anna Millar,Paul J. Taylor,Keiryn L. Bennett,Kelly Boutilier,Lingyun Yang,Cheryl Wolting,Ian Donaldson,Søren Schandorff,Juanita Shewnarane,Mai Vo,Joanne Taggart,Marilyn Goudreault,Brenda Muskat,Cris Alfarano,Danielle Dewar,Zhen Lin,Katerina Michalickova,Katerina Michalickova,Andrew Willems,Andrew Willems,Holly Sassi,Peter A Nielsen,Karina Juhl Rasmussen,Jens R. Andersen,Lene E. Johansen,Lykke Haastrup Hansen,Hans Jespersen,Alexandre V. Podtelejnikov,Eva Nielsen,Janne S. Crawford,Vibeke Poulsen,Birgitte D Sørensen,Jesper Matthiesen,Ronald C. Hendrickson,Frank Gleeson,Tony Pawson,Tony Pawson,Michael Moran,Daniel Durocher,Daniel Durocher,Matthias Mann,Christopher W. V. Hogue,Christopher W. V. Hogue,Daniel Figeys,Mike Tyers,Mike Tyers +52 more
TL;DR: Comparison of the HMS-PCI data set with interactions reported in the literature revealed an average threefold higher success rate in detection of known complexes compared with large-scale two-hybrid studies.
Journal ArticleDOI
Large‐scale mapping of human protein–protein interactions by mass spectrometry
Rob M. Ewing,Peter Chu,Fred Elisma,Hongyan Li,Paul J. Taylor,Shane Climie,Linda McBroom-Cerajewski,Mark D. Robinson,Liam O'Connor,Michael Li,Rod Taylor,Moyez Dharsee,Yuen Ho,Adrian Heilbut,Lynda Moore,Shudong Zhang,Olga Ornatsky,Yury V. Bukhman,Martin Ethier,Yinglun Sheng,Julian Vasilescu,Mohamed Abu-Farha,Jean-Philippe Lambert,Henry S. Duewel,Ian I. Stewart,Bonnie Kuehl,Kelly Hogue,Karen Colwill,Katharine Gladwish,Brenda Muskat,Robert Kinach,Sally Lin Adams,Michael Moran,Gregg B. Morin,Thodoros Topaloglou,Daniel Figeys +35 more
TL;DR: In‐depth mining of the data set shows that it represents a valuable source of novel protein–protein interactions with relevance to human diseases, and via the preliminary analysis, many novel protein interactions and pathway associations are reported.
Journal ArticleDOI
Synergistic drug combinations tend to improve therapeutically relevant selectivity.
Joseph Lehar,Andrew S Krueger,William Avery,Adrian Heilbut,Lisa M. Johansen,E. Roydon Price,Richard Rickles,Glenn F. Short,Jane Staunton,Xiaowei Jin,Margaret S. Lee,Grant R. Zimmermann,Alexis Borisy +12 more
TL;DR: Evidence is provided that synergistic drug combinations are generally more specific to particular cellular contexts than are single agent activities, and six combinations whose selective synergy depends on multitarget drug activity are highlighted.
Journal ArticleDOI
Sequencing Chromosomal Abnormalities Reveals Neurodevelopmental Loci that Confer Risk across Diagnostic Boundaries
Michael E. Talkowski,Jill A. Rosenfeld,Ian Blumenthal,Vamsee Pillalamarri,Colby Chiang,Adrian Heilbut,Carl Ernst,Carrie Hanscom,Elizabeth J. Rossin,Elizabeth J. Rossin,Amelia M. Lindgren,Shahrin Pereira,Douglas M. Ruderfer,Douglas M. Ruderfer,Andrew Kirby,Andrew Kirby,Stephan Ripke,Stephan Ripke,David J. Harris,Ji Hyun Lee,Kyungsoo Ha,Hyung Goo Kim,Benjamin D. Solomon,Andrea L. Gropman,Andrea L. Gropman,Diane Lucente,Katherine B. Sims,Toshiro K. Ohsumi,Mark L. Borowsky,Stephanie Loranger,Bradley J. Quade,Kasper Lage,Judith H. Miles,Bai-Lin Wu,Bai-Lin Wu,Bai-Lin Wu,Yiping Shen,Benjamin M. Neale,Benjamin M. Neale,Lisa G. Shaffer,Mark J. Daly,Cynthia C. Morton,Cynthia C. Morton,Cynthia C. Morton,James F. Gusella +44 more
TL;DR: The findings suggest a polygenic risk model of autism and reveal that some neurodevelopmental genes are sensitive to perturbation by multiple mutational mechanisms, leading to variable phenotypic outcomes that manifest at different life stages.
Journal ArticleDOI
Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
Kyle Northcote Cowan,Adrian Heilbut,Tilman Humpl,Catherine G. Lam,Shinya Ito,Marlene Rabinovitch +5 more
TL;DR: It is reported that elastase inhibitors can reverse advanced pulmonary vascular disease produced in rats by injecting monocrotaline, an endothelial toxin, and oral administration of these inhibitors resulted in 92% survival, compared with 39% survival in untreated or vehicle-treated rats.